# Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.

> PubMed lists PMID 33615100 in JBMR plus as Published Erratum, with publication-date metadata of 2020-11-03 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33615100-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33615100-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-33615100-abaloparatide-v1.json
- Content SHA-256: `4b0d5361535d2ebaaec61d388934c996ce288edd2a53349730ab5d4cfaa2de86`

## Claims and source pins

### Headline

Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study. ([`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`](#source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac))

### Summary

PubMed lists PMID 33615100 in JBMR plus as Published Erratum, with publication-date metadata of 2020-11-03 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`](#source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac))

### Paragraph 1

PubMed lists PMID 33615100 in JBMR plus as Published Erratum, with publication-date metadata of 2020-11-03 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`](#source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`](#source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac))

## Sources

<a id="source-pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac"></a>
- **Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study. · retained source version 1:2021-02-23:current:5e4e601601ac9c46349bf3a26bf1f6e02bd15b3465ecec853a73edc7521e816a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33615100/) (`pubmed-observation-pmid-33615100-2021-02-23-5e4e601601ac`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-33615100-abaloparatide-v1.json SHA-256: 4b0d5361535d2ebaaec61d388934c996ce288edd2a53349730ab5d4cfaa2de86.